Ataxia Charlevoix-Saguenay Foundation
In 2006, the Foundation was created and funded the first research to be undertaken since the identification of the Ataxia gene in 2000. It was crucial to begin research in order to discover a treatment for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).
Since its creation, the Foundation has funded several research projects related to this neurological disorder. The Foundation is a charitable organization and is supported entirely by private donations and volunteers who support the cause.
Research Objectives
The main research objective of the Ataxia Charlevoix-Saguenay Foundation is to develop a treatment for ARSACS. Every year the Foundation financed several research projects in Canada and abroad. The efforts of the Foundation are concentrated currently in three main research areas:
Financing of several promising research projects with reearchers that are experts in this field.
Forming partnerships with other organizations and pharmaceutical companies to further the understanding of this disease and conduct independent research.
Conducting clinical trials
Scientific Advisory Board
All applications for research grants are evaluated by the Scientific Advisory Board of the Ataxia of Charlevoix-Saguenay Foundation according to specific criteria.
Research Grants
To further encourage and accelerate the development of a treatment for ARSACS, the Ataxia Charlevoix-Saguenay Foundation provides grants and opportunities to researchers.
This year, the call for proposals of the Ataxia of Charlevoix-Saguenay Foundation is jointly supported by the “Richardson Research Fund” to fund ARSACS research projects.
As part of this funding offer, the Ataxia Charlevoix-Saguenay Foundation in collaboration with the “Richardson Research Fund” offers up to a maximum of $100,000 CAD per project and up to $25,000 CAD per project to support start-up initiatives (Seed Grant).
Both types of grants are awarded for a 12-month period, with the possibility of renewal. For more information and to apply : ARSACS Call for Proposals and Application Form.
ARSACS Research Projects
2026-2027
The Foundation gratefully acknowledges the generous support of the Richardson Trust Fund and Action for ARSACS Foundation USA (AFA) in helping fund the 2026–2027 ARSACS research projects.
The Krogan Lab team continues working on ARSACS
The Krogan Lab researchers are currently performing mechanistic follow-up studies on a subset of the protein-protein interactions they identified. “Our affinity purification mass spectrometry studies on sacsin have revealed a protein-proteininteraction with DAPK...
The Krogan Lab team continues working on ARSACS
The Krogan Lab researchers are currently performing mechanistic follow-up studies on a subset of the protein-protein interactions they identified. “Our affinity purification mass spectrometry studies on sacsin have revealed a protein-proteininteraction with DAPK...
L’équipe du Krogan Lab continue la recherche sur l’ARSACS
Les chercheurs du Krogan Lab effectuent actuellement des études de suivi sur un sous-ensemble des interactions protéine-protéine qu'ils ont indentifiées. Résumé des dernières découvertes.
The Krogan Lab team continues working on ARSACS
The Krogan Lab researchers are currently performing mechanistic follow-up studies on a subset of the protein-protein interactions they identified. Summary of recent findings.
Recherche des Drs Wolter et Chapple publiée
La recherche des Drs Justin Wolter et Paul Chapple " Multi-omic profiling reveals the ataxia protein sacsin is required for integrin trafficking and synaptic organization" a été publiée dans Cell Reports le 1er novembre 2022. Un communiqué de presse a été émis par...
Drs Wolter & Chapple’s ARSACS research published
Drs Justin Wolter and Paul Chapple' s ARSACS research "Multi-omic profiling reveals the ataxia protein sacsinis required for integrin trafficking and synaptic organization" has been published in the Cell Reports on November 1, 2022. Furthermore, the University of...
Multi-omic profiling reveals the ataxia protein sacsin is required for integrin trafficking and synaptic organization
Multi-omic profiling reveals the ataxia protein sacsin is required for integrin trafficking and synaptic organization – Dr. Justin Wolter, Dr. Paul Chapple. Research article published in Cell Reports..
$940,000 for ARSACS research in 2022-2023!
As part of its mission, the Foundation is financing 15 teams of researchers in Quebec/Canada and internationally for a total amount of $940,000 for 2022-2023. 10 promissing projects whose objective is to discover a treatment for ARSACS. Project description.
940 000$ pour la recherche sur l’ARSACS!
Dans le cadre de sa mission, la Fondation finance 15 équipes de chercheurs au Québec/Canada et à l'international pour une somme totale de 940 000$ en 2022-2023 . 10 projets prometteurs dont l'objectif est de découvrir un traitement pour l'ARSACS. Description des...
“Elucidating mechanisms underlying motor coordination rescue in a mouse model of ARSACS” – Dr. Alanna Watt and Dr. Anne McKinney
One of the hallmark features of ARSACS is dysfunction and eventual death of Purkinje cells in the cerebellum, which contributes to ataxia. Strikingly, not all Purkinje cells become ill and die: rather, specific patterns of vulnerability and resilience to cell death...
“Charting the neurodevelopmental stage of ARSACS (NeurodevARSACS): A cross-species longitudinal characterization of the early molecular changes in the brain, CSF and blood”- Drs Justin Wolter, Matthis Synofzik and David Mengel
It is well established in neurodegenerative diseases that early therapeutic intervention - ideally before neurodegenerative cascades begin to breakdown neuronal function - is key to the success of disease-modifying therapies. Yet we do not understand the early...
“Therapeutic Approaches for ARSACS”- Dr. Benoit Gentil and Dr. Heather Durham
Dr. Heather Durham ARSACS is characterised by the lack of sacsin expression, and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies. Our strategy over the last years has been aimed at developing a replacement therapy,...
“Unraveling the role of glial cells in ARSACS Rationale” – Drs Federico Herrera, Adelaide Fernandes and Michelle Adams
Glial cells play key roles in developmental and neurodegenerative disorders, including some with remarkable similarities with ARSACS, such as Alexander disease and Giant Axonal Neuropathy. We and others have found high levels of sacsin expression in rodent and human...
“Metabolic rewiring in cellular models of ARSACS” – Dr. Paul Chapple
The viability of neurons in the brain depends on a complex series of interconnected biochemical reactions that constitute cellular metabolism. Disruption of these metabolic pathways is associated with neurological conditions, including Alzheimer’s and Parkinson’s....
“Identifying Clinically Relevant Compounds and Their Molecular Targets Modulating the Purkinje Neuronal Excitability in ARSCAS patients”- Dr.Mohan Babu
Despite extensive research, the underlying causes of neurodegeneration in ARSACS still remain unclear, and thus there is a need for identifying effective therapies for ARSACS patients. My lab over the past several years has focused on characterizing the changes of...
“Targeting transmembrane ion balance to restore Purkinje cell functionality in ARSACS” – Dr. Francesca Maltecca
We identified in murine Purkinje cells a specific interaction of sacsin with proteins regulating transmembrane ion balance, which are required for tuning the firing properties of these neurons. Our functional studies support a deregulation of ion conductance in...
“Structural Determination and Super Resolution Imaging of Sacsin” – Dr. Walid Houry
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a juvenile progressive movement disorder caused by mutations in a gene called SACS, which produces a protein with the same name (SACS or sacsin). The disease is characterized by very early onset,...
“Retinal pigment epithelium (RPE) cell system to uncover the molecular mechanisms of ARSACS – related retinal effects” – Dr. Daniele Galatolo
Retinal and eye abnormalities are among the clinical hallmarks in ARSACS and have been described since first reports. Those defects have been confined to an unexplored field by a molecular point of view, compared to those related to brain and cerebellum that have...
“Effect of neuroprotective molecules dietary supplementation on ARSACS zebrafish model development”- Dr. Valentina Naef
ARSACS is incurable neurodegenerative disorder and there is an urgent need to define new therapies. The expected results of this project are to evaluate, through preclinical studies, the effectiveness and usefulness of an experimental diet containing neuroprotective...
“Elucidating mechanisms underlying motor coordination rescue in a mouse model of ARSACS” – Drs. Alanna Watt & Anne McKinney
One of the hallmark features of ARSACS is dysfunction and eventual death of Purkinje cells in the cerebellum, which contributes to ataxia. Strikingly, not all Purkinje cells become ill and die: rather, specific patterns of vulnerability and resilience to cell death...
“Charting the neurodevelopmental stage of ARSACS (NeurodevARSACS): A cross-species longitudinal characterization of the early molecular changes in the brain, CSF and blood” – Drs. Justin Wolter, Matthis Synofzik & David Mengel
It is well established in neurodegenerative diseases that early therapeutic intervention - ideally before neurodegenerative cascades begin to breakdown neuronal function - is key to the success of disease-modifying therapies. Yet we do not understand the early...
“Therapeutic Approaches for ARSACS”- Drs. Benoit Gentil and Heather Durham
ARSACS is characterised by the lack of sacsin expression, and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies. Our strategy over the last years has been aimed at developing a replacement therapy, by peptide and/or...
“Unraveling the role of glial cells in ARSACS Rationale” – Drs. Federico Herrera, Adelaide Fernandes & Michelle Adams
Glial cells play key roles in developmental and neurodegenerative disorders, including some with remarkable similarities with ARSACS, such as Alexander disease and Giant Axonal Neuropathy. We and others have found high levels of sacsin expression in rodent and human...
“Metabolic rewiring in cellular models of ARSACS” – Dr.Paul Chapple
The viability of neurons in the brain depends on a complex series of interconnected biochemical reactions that constitute cellular metabolism. Disruption of these metabolic pathways is associated with neurological conditions, including Alzheimer’s and Parkinson’s....
“Identifying Clinically Relevant Compounds and Their Molecular Targets Modulating the Purkinje Neuronal Excitability in ARSACS patients” – Dr.Mohan Babu
Despite extensive research, the underlying causes of neurodegeneration in ARSACS still remain unclear, and thus there is a need for identifying effective therapies for ARSACS patients. My lab over the past several years has focused on characterizing the changes of...
“Targeting transmembrane ion balance to restore Purkinje cell functionality in ARSACS” – Dr. Francesca Maltecca
We identified in murine Purkinje cells a specific interaction of sacsin with proteins regulating transmembrane ion balance, which are required for tuning the firing properties of these neurons. Our functional studies support a deregulation of ion conductance in...
“Structural Determination of Sacsin” – Dr. Walid Houry
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a juvenile progressive movement disorder caused by mutations in a gene called SACS, which produces a protein with the same name (SACS or sacsin). The disease is characterized by very early onset,...
“Retinal pigment epithelium (RPE) cell system to uncover the molecular mechanisms of ARSACS – related retinal effects” – Dr. Daniele Galatolo
Retinal and eye abnormalities are among the clinical hallmarks in ARSACS and have been described since first reports. Those defects have been confined to an unexplored field by a molecular point of view, compared to those related to brain and cerebellum that have been...
“Effect of neuroprotective molecules dietary supplementation on ARSACS zebrafish model development”- Dr. Valentina Naef
ARSACS is incurable neurodegenerative disorder and there is an urgent need to define new therapies. The expected results of this project are to evaluate, through preclinical studies, the effectiveness and usefulness of an experimental diet containing neuroprotective...
Merci pour votre participation!
Merci d'avoir participé aux sondages PROSPAX. Les résultats seront utilisés pour développer un outil d' évaluation pour mesurer les changements chez une personne vivant avec l'ARSACS au fil du temps. Résultats du sondage.
Thank you !
Thank you for participating in the PROSPAX surveys! There was a good response and your input will be used to develop an assessment tool to measure changes in a person living with ARSACS over time. Survey results.
“Diner des Producteurs” under the Honorary Presidency of Mr. Vincent Chiara
Mr. Chiara, president and founder of MACH, is one of the main players in the real estate field in Quebec and Canada. The 15th edition of the “Diner des Producteurs”, annual fundraising event for ARSACS, will take place on October 27,2022. Reservation form.
“Diner des Producteurs” sous la présidence d’honneur de M. Vincent Chiara
M. Chiara, président et fondateur de MACH, est un des principaux acteurs dans le domaine immobilier au Québec et au Canada. La 15e édition du "Diner des Producteurs", événement-bénéfice annuel pour l'ARSACS , aura lieu le 27 octobre 2022. Formulaire de...
PROSPAX and TREAT-ARCA Meeting in July 2022
In July 2022, the PROSPAX and TREAT-ARCA consortia held a joint annual meeting in Berlin, Germany, including researchers, clinicians, and representatives from Euro-ataxia and the Ataxia Charlevoix-Saguenay Foundation. A fantastic opportunity for researchers around the...
Réunion PROSPAX & TREAT-ARCA en juillet 2022
En juillet 2022, les consortiums PROSPAX et TREAT-ARCA ont tenu une réunion conjointe à Berlin, en Allemagne incluant chercheurs, cliniciens et représentants d'Euro-ataxie et de la Fondation Ataxie Charlevoix-Saguenay. Une opportunité fantastique de se rencontrer,...
Publication de la recherche du Dr Babu
L'article du Dr Mohan Babu publié par Elsevier en septembre 2022. Dr Babu fait partie de l'équipe de chercheurs ARSACS et a reçu du financement de la Fondation pour ce projet. Elsevier est une société d'édition universitaire spécialisée dans le contenu scientifique,...
Dr. Babu’s ARSACS article published
Dr. Mohan Babu's article was published by Elsevier in September 2022. Dr. Babu is part of the ARSACS research team and has received funding from the Foundation for this project. Elsevier is an academic publishing company specializing in scientific, technical, and...
Insights into SACS pathological attributes in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)
Insights into SACS pathological attributes in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) – Dr. Mohan Babu. Research published by Elsevier in September 2022..
Diner Des Producteurs 2022
Registration/sponsorship/donation form
Formulaire de commandite, de réservation et de don
“Molecular characterisation of sacsin deficient cells”
Research report from Dr. Paul Chapple, Barts and London Queen Mary’s School of Medicine and Dentistry, London UK – a 3 year project financed by the Foundation.
“Molecular characterisation of sacsin deficient cells”
Rapport du projet de recherche du Dr Paul Chapple, Barts and London Queen Mary’s School of Medicine and Dentistry, London UK - un projet échelonné sur 3 ans et financé par la Fondation.
ARSACS around the word
30 countries are represented in the ARSACS International Patient Registry. Map of registrants. To all of you who are registered, thank you for your participation and for helping the research. The registry is an essential tool for advancing research and for clinical...
ARSACS à travers le monde
Des personnes provenant de 30 pays sont inscrites au Registre International des Personnes Atteintes de l'ARSACS. Carte des personnes inscrites. À tous ceux qui sont inscrits , merci de votre participation et d'aider la recherche. Le registre est un outil essentiel...
Rapport de recherche du Dr Houry
Rapport de la recherche “Structural Determination and Super Resolution Imaging of Sacsin”, projet sous la direction du Dr Walid Houry de l'Université de Toronto et financé par la Fondation en 2021-2022. ( disponible en version anglaise seulement).
Dr. Houry’s research report
“Structural Determination and Super Resolution Imaging of Sacsin” research report under the leadership of Dr. Houry from the University of Toronto and funded by the Foundation in 2021-2022.
Molecular characterisation of sacsin deficient cells – by Dr. Paul Chapple, Barts and London Queen Mary’s School of Medicine
Molecular characterisation of sacsin deficient cells – by Dr. Paul Chapple, Barts and London Queen Mary’s School of Medicine funded by the Foundation in 3 year period
Structural Determination and Super Resolution Imaging of Sacsin – by Dr. Walid Houry, University of Toronto
Structural Determination and Super Resolution Imaging of Sacsin – by Dr. Walid Houry, University of Toronto funded by the Foundation in 2021-2022
Projet TREAT-ARCA
Le projet TREAT-ARCA, qui a débuté en juin 2021, est un projet de recherche préclinique axé sur deux ataxies rares : l'ARSACS et l'ataxie-COQ8A. Les objectifs sont de tester 2 médicaments réutilisés plus des nouveaux pour l'ARSACS, de tester la thérapie génétique et...
TREAT- ARCA Research Project
The TREAT-ARCA project, which began in June 2021, is a pre-clinical research project focused on two rare ataxias: ARSACS and COQ8A-ataxia. The objectives are to test promising repurposed and novel drugs for ARSACS, to test gene therapy and identify and validate...
Clinical and Molecular Findings of Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay: an Iranian Case Series Expanding the Genetic and Neuroimaging Spectra
Clinical and Molecular Findings of Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay: an Iranian Case Series Expanding the Genetic and Neuroimaging Spectra – . Research conducted in Iran and published in The Cerebellum in 2022..
“Discovery of new targets for therapeutic interventions in ARSACS disease”- rapport du Krogan Lab
Rapport de recherche du laboratoire Krogan à l'UCSF pour le projet "Discovery of new targets for therapeutic interventions in ARSACS disease", projet sous la direction du Dr Nevan Krogan et financé par la Fondation en 2020-2021.
“Discovery of new targets for therapeutic interventions in ARSACS disease”- Krogan Lab’s report
Research report from the Krogan Lab at UCSF for the project "Discovery of new targets for therapeutic interventions in ARSACS disease", project under the leadership of Dr. Nevan Krogan and funded by the Foundation in 2020-2021.
Discovery of new targets for therapeutic interventions in ARSACS disease – by Krogan Lab, UCSF
Discovery of new targets for therapeutic interventions in ARSACS disease – by Krogan Lab, UCSF Project funded by the Foundation in 2020-2021
Recessive cerebellar and afferent Ataxias – clinical challenges and future directions
Recessive cerebellar and afferent Ataxias – clinical challenges and future directions – Dr. Nicolas Dupré. Published in Nature Reviews | Neurology journal..
Publication de la recherche du Dr Dupré et son équipe
La recherche du Dr Nicolas Dupré et de son équipe, “Recessive cerebellar and afferent Ataxias – clinical challenges and future directions”, a été publiée dans le journal Nature Reviews | Neurology, le 24 mars 2022.
Dr. Dupré and his team published research
“Recessive cerebellar and afferent Ataxias – clinical challenges and future directions”, research article by Dr. Nicolas Dupré and his team published in the Nature Reviews | Neurology journal on March 24, 2022.
ARSACS OVD finances 2 projets en Italie (80.450€)
L' Organizzazione di volontariato (ODV) finances 2 projets ARSACS avec la collaboration de la the Fondation Telethon. Description des projets. ODV est une organisation de bénévoles fondée pas Susanna Deluca et Dr Paolo Arrigoni et dédiée à la cause ARSACS. Telethon...
“Danio Rerio as a model to reveal new insight of retinal defects in ARSACS”- Dr. Valentina Naef
The ataxia of Charlevoix-Saguenay is a rare neurodevelopmental condition associated with structural retinal abnormalities. Mouse models cannot help to clarify this feature. This project will investigate retinal defects driven by the loss of SACS using...
“Corticospinal tract microstructural integrity and its correlation with clinical and molecular biomarkers: a profilometry MRI study to identify in-vivo biomarkers of disease severity in ARSACS”- Dr. Sirio Cocozza
Patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) encounter symptoms that affect their walking ability. Among these, they show abnormal tensing of the muscles (spasticity), which partly derives from the disruption of a bundle of fibers...
ARSACS OVD finances 2 projects in Italy (80.450€)
The Organizzazione di volontariato (ODV) finances 2 ARSACS projects with the support from the Fondazione Telethon. Project details. ODV is a volunteer organisation founded by Susanna Deluca and Dr. Paolo Arrigoni and dedicated to the ARSACS...
“Danio Rerio as a model to reveal new insight of retinal defects in ARSACS”- Dr. Valentina Naef
The ataxia of Charlevoix-Saguenay is a rare neurodevelopmental condition associated with structural retinal abnormalities. Mouse models cannot help to clarify this feature. This project will investigate retinal defects driven by the loss of SACS using...
“Corticospinal tract microstructural integrity and its correlation with clinical and molecular biomarkers: a profilometry MRI study to identify in-vivo biomarkers of disease severity in ARSACS”- Dr. Sirio Cocozza
Patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) encounter symptoms that affect their walking ability. Among these, they show abnormal tensing of the muscles (spasticity), which partly derives from the disruption of a bundle of fibers...
Visionez l’histoire inspirante d’Ally
Dans le cadre de la Journée des Maladies Rares, visionez l'histoire inspirante d'Ally et de sa famille. Nous sommes motivés par son courage, sa force et sa détermination à trouver un traitement pour l'ARSACS.
Watch Ally’s inspiring story
In light of Rare Disease Day, watch the inspiring story of Ally and her family. We are motivated by her courage, her strength and her determination in finding a treatment for ARSACS.
PROSPAX Survey – Deadline extended to March 6
Thank you if you have completed already the PROSPAX survey #2. We still need a greater representation of people with ARSACS for the research. Therefore, the deadline has been extended to Sunday March 6. Please take few minutes to provide your insight so people with...
Sondage PROSPAX : Prolongé jusqu’au 6 mars
Si vous avez déjà répondu au sondage Prospax #2, nous vous en remercions. Nous avons besoin d’une plus grande représentation des personnes atteintes de l’ARSACS dans le cadre du projet PROSPAX. Il est encore possible de participer au sondage. La date limite a été...
“Du calcium bien ciblé pourrait être une option thérapeutique pour l’ARSACS” – Dre Maltecca
Résumé de la recherche du Dre Maltecca “Targeting deregulated calcium homeostasis as potential therapeutic option for ARSACS“. Les résultats indiquent que du calcium bien ciblé peut représenter une option thérapeutique pour l'ARSACS. ( résumé en version anglaise...
“Targeting calcium may represent a therapeutic option for ARSACS” – Dr. Maltecca’s research project
Brief summary of the results of Dr. Maltecca's research project "Targeting deregulated calcium homeostasis as potential therapeutic option for ARSACS". The results indicate that targeting calcium may represent a therapeutic option for ARSACS.
PROSPAX Sondage Phase 2
Opportunité de vous faire entendre. Faites savoir aux chercheurs ce qui est important pour vous et comment vous vous sentez vivant avec la maladie. Vous n’avez pas besoin d’avoir répondu au premier sondage pour répondre à ce sondage. Un parent d'un enfant peut remplir...
PROSPAX Phase 2 Survey
Make your voice heard. Let researchers know what is important to you and how you feel living with the condition.You do not need to have completed the first survey to fill out this survey. A parent of a child can fill out the survey. PROSPAX is a 3 year...
Invitation à soumettre votre projet de recherche sur l’ARSACS
Si vous êtes intéressé à vous joindre à l’équipe internationale de chercheurs pour faire avancer la compréhension de l'ARSACS afin de développer un traitement, veuillez nous envoyer votre proposition. Pour plus de détails: Offre de financement et Annexe ARSACS. Date...
Invitation to submit your ARSACS research proposal
If you are interested in joining the team of researchers around the world to advance the understanding of ARSACS and lead to a treatment, please send us your proposal. For details : Financing Offer and ARSACS Appendix. Deadline : May 27, 2022.
Recherche sur l’ARSACS au Portugal
La recherche sur l'ARSACS du Dr Federico Herrera et son équipe, “Sacsin Deletion Induces Aggregation of Glial Intermediate Filaments", publiée dans le Cells Journal le 16 janvier 2022.
ARSACS research in Portugal
ARSACS research conducted by Dr. Federico Herrera and his team in Portugal,“Sacsin Deletion Induces Aggregation of Glial Intermediate Filaments” , published in the Cells Journal on January 16, 2022.
Sacsin Deletion Induces Aggregation of Glial Intermediate Filaments
Sacsin Deletion Induces Aggregation of Glial Intermediate Filaments – Dr. Federico Herrera. Research published in the Cells Journal on January 16, 2022..
Projet de recherche sur l’ARSACS à CBC Radio
Le projet de recherche sur l'ARSACS, dirigé par les Drs Mckinney,Watt et Toscano- Marquez, a été présenté à l'émission “Let’s Go” de CBC radio le 2022-01-20. Dans le cadre du segment "Comprendre le cerveau", Rackeb Tesfaye, chroniqueuse scientifique et étudiante au...
ARSACS research featured on CBC Radio
ARSACS research project, led by Drs. Mckinney ,Watt and Toscano- Marquez, was featured on CBC radio "Let's Go" on 2022-01-20. As part of the "Understanding the Brain" segment, Rackeb Tesfaye, science columnist at CBC radio and a PHD candidate in neurosciences,...
1,250 M$ net pour la recherche sur l’ARSACS lors du Diner des Producteurs
"À vous tous : Monsieur Marc Bédard, président d’honneur, commanditaires, partenaires, donateurs et bénévoles, c’est grâce à vous que la Fondation peut poursuivre sa mission. Merci pour votre soutien!" Jean Groleau , président de la Fondation de l'Ataxie...
$1.250M net raised for ARSACS research at the Diner des Producteurs
” To all of you : Mr. Marc Bédard, Honorary President, sponsors, partners, donors and volunteers, it is thanks to you that the Foundation can pursue it’s mission. Thank you! ” Jean Groleau , president of the Ataxia Charlevoix-Saguenay Foundation. The Diner des...
Une découverte surprenante par l’équipe de chercheurs à McGill : toutes les cellules zébrin-négatives ne se comportent pas de la même manière
Communiqué de presse de l’Université McGill, Montréal - Des chercheurs de l’Université McGill, dirigés par les Dres Alanna Watt et Anne Mckinney, ont fait un grand pas en avant dans la compréhension de la cause de l’ARSACS. « Nous avons montré très clairement que...
McGill ARSACS researchers team made a surprising discovery: not all zebrin-negative cells behave the same
Latest news release from McGill University, Montreal- Researchers at McGill University, lead by Drs. Alanna Watt and Anne Mckinney, have made an important step forward in understanding the cause of ARSACS. “We have shown really clearly that zebrin-negative cells in...
Dr Pandolfo se joint au conseil de la Fondation
La Fondation de l'Ataxie Charlevoix-Saguenay est heureuse d’annoncer que le Dr Massimo Pandolfo s’est joint à son conseil d’administration. Dr Pandolfo est professeur de neurologie à l’Université McGill à Montréal depuis janvier 2021. Auparavant, il a été professeur...
Dr. Pandolfo joins the Foundation’s Board
The Ataxia Charlevoix-Saguenay Foundation is pleased to announce that Dr. Massimo Pandolfo has joined its board of directors. Dr. Pandolfo is Professor of Neurology at McGill University in Montreal since January 2021. Prior, he was Professor of neurology and Director...
Drs. Nethisinghe and Giunti’ s ARSACS research published
Research of Drs. Nethisinghe and Giunti, "Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS", was published in the International Journal of Molecular Sciences in October 2021. This research was made possible thanks to the Foundation in collaboration with...
Publication de la recherche des Drs Nethisinghe et Giunti
L'article "Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS" publié dans l'International Journal of Molecular Sciences en octobre 2021. Cette recherche a été rendue possible grâces à la Fondation en collaboration avec l'University College London...
Me Jean Groleau named Vice-President of Catalis Board of Directors
Me Jean Groleau, co-founder and president of the Fondation de l'Ataxie Charlevoix-Saguenay, is proud to join Catalis to represent the needs and challenges of people with rare diseases. Launched in 2017, CATALIS' mandate is, among other things, to facilitate...
Me Groleau nommé à titre de vice-président du conseil d’ administration de Catalis
Me Jean Groleau, co-fondateur et président de la Fondation de l'Ataxie Charlevoix-Saguenay, est fier de se joindre à Catalis pour représenter les besoins et les défis des personnes atteintes de maladies rares. Lancé en 2017, CATALIS a comme mandat, entre autres, de...
La Fondation a besoin de votre soutien
La campagne de financement de la Fondation est en cours jusqu’à la fin de décembre. Nous avons besoin de votre soutien pour poursuivre la recherche sur l'ARSACS. Ensemble, nous pouvons travailler à l’atteinte de l’objectif d’améliorer la vie des personnes touchées par...
The Foundation needs your support
The Foundation's fundraising campaign is underway until the end of December. We need your support to pursue our mission to finance ARSACS research. Together we can work toward the goal of making lives better for individuals affected by ARSACS. Research needs money....
The 6th International Symposium on ARSACS – A success!
More than 200 participants from different backgrounds (academic, pharmaceutical and people with ARSACS) participated in the Symposium. An international network of ARSACS researchers who shared their research progress in a climate of collaboration and exchange of...
Un succès! le 6ième Symposium International sur l’ARSACS
Plus de 200 personnes provenant de différents milieux (universitaire, pharmaceutique et personnes atteintes de l’ARSACS) ont participé au Symposium. Un réseau international de chercheurs sur l'ARSACS qui ont partagé leurs recherches dans un climat de collaboration et...
Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS
Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS – Dr. Suran Nethisingle, Dr. Paola Giunti. Published in the International Journal of Molecular Medicine in October 2021..
Molecular identity and location influence Purkinje cell vulnerability in ARSACS mice
Molecular identity and location influence Purkinje cell vulnerability in ARSACS mice – Dr. Alanna Watt, Dr. Anne McKinney. Published in the Frontiers Journal..
Excellente opportunité de faire de la recherche sur l’ARSACS en Italie
L’Organizzazione di volontariato (ODV) offre un financement de démarrage de 50 000 € pour la recherche sur l’ARSACS en partenariat avec la Fondazione Telethon. Cette opportunité s’adresse aux chercheurs en Italie. Cependant, un projet impliquant une collaboration...